WP760, a melanoma selective drug

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 5, 2007, Pages 625-633

  Zheng, Mingzhong ^a   Priebe, Waldemar ^a   Walch, Eugene T ^a   Roth, Katherine G ^a   Han, Mikyung ^a   Tang, Chi Hui ^a   Lee, Sangkyou ^a   Poindexter, Nancy J ^a   Fokt, Izabela ^a   Grimm, Elizabeth A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Cell cycle; iNOS; Melanoma; WP760

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CASPASE 3; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PROTEIN P53; UNCLASSIFIED DRUG; WP 760;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MELANOMA; PRIORITY JOURNAL; UPREGULATION; WESTERN BLOTTING;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL CYCLE; CELL DIVISION; DRUG EVALUATION, PRECLINICAL; ENZYME ACTIVATION; HUMANS; MELANOMA; MITOCHONDRIA; NITRIC OXIDE SYNTHASE TYPE II; TUMOR CELLS, CULTURED;

EID: 34547850379     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0404-5     Document Type: Article

References (33)

1. Grossman D, Altieri DC (2001) Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev 20:3-11
2. Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22:3138-3151
3. Tang CH, Grimm EA (2004) Depletion of endogenous nitric oxide enhances cisplatin-induced apoptosis in a p53-dependent manner in melanoma cell lines. J Biol Chem 279:288-298
4. Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM (2003) Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res 63:8330-8337
5. Stewart AL, Mhashilkar AM, Yang XH, Ekmekcioglu S, Saito Y, Sieger K, Schrock R, Onishi E, Swanson X, Mumm J B, Zumstein L, Watson G J, Snary D, Roth J A, Grimm E A, Ramesh R, Chada S (2002) PI3 kinase blockade by Ad-PTEN inhibits invasion and induces apoptosis in RGP and metastatic melanoma cells. Mol Med 8:451-461
6. Dhawan P, Singh AB, Ellis DL, Richmond A (2002) Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 62:7335-7342
7. Priebe W, Fokt I, Przewloka T, Chaires JB, Portugal J, Trent JO (2001) Exploiting anthracycline scaffold for designing DNA-targeting agents. Methods Enzymol 340:529-555
8. Chaires JB, Leng F, Przewloka T, Fokt I, Ling YH, Perez-Soler R, Priebe W (1997) Structure-based design of a new bisintercalating anthracycline antibiotic. J Med Chem 40:261-266
9. Robinson H, Priebe W, Chaires JB, Wang AH (1997) Binding of two novel bisdaunorubicins to DNA studied by NMR spectroscopy. Biochemistry 36:8663-8670
10. Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA (2006) Regulation of iNOS by the p4/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene 25:3956-62
11. Chang JY, Chavis JA, Liu LZ, Drew PD (1998) Cholesterol oxides induce programmed cell death in microglial cells. Biochem Biophys Res Commun 249:817-821
12. Han C, Leng J, Demetris AJ, Wu T (2004) Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res 64:1369-1376
13. Hattori H, Kuroda M, Ishida T, Shinmura K, Nagai S, Mukai K, Imakiire A (2004) Human DNA damage checkpoints and their relevance to soft tissue sarcoma. Pathol Int 54:26-31
14. Zhang XM, Xu Q (2001) Metastatic melanoma cells escape from immunosurveillance through the novel mechanism of releasing nitric oxide to induce dysfunction of immunocytes. Melanoma Res 11:559-567
15. Ko LJ, Prives C (1996) p53: puzzle and paradigm. Genes Dev 10:1054-1072
16. Lebedeva IV, Su ZZ, Sarkar D, Fisher PB (2003) Restoring apoptosis as a strategy for cancer gene therapy: focus on p53 and mda-7. Semin Cancer Biol 13:169-178
17. May P, May E (1999) Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18:7621-7636
18. Lowe SW (1995) Cancer therapy and p53. Curr Opin Oncol 7:547-553
19. Feleszko W, Mlynarczuk I, Olszewska D, Jalili A, Grzela T, Lasek W, Hoser G, Korczak-Kowalska G, Jakobisiak M (2002) Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. Int J Cancer 100:111-118
20. Liu JD, Wang YJ, Chen CH, Yu CF, Chen LC, Lin JK, Liang YC, Lin SY, Ho YS (2003) Molecular mechanisms of G0/G1 cell-cycle arrest and apoptosis induced by terfenadine in human cancer cells. Mol Carcinog 37:39-50
21. McGowan CH (2002) Checking in on Cds1 (Chk2): a checkpoint kinase and tumor suppressor. Bioessays 24:502-511
22. Bartek J, Falck J, Lukas J (2001) CHK2 kinase-a busy messenger. Nat Rev Mol Cell Biol 2:877-886
23. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L (2003) ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 63:1684-1695
24. Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954
25. Lala PK, Orucevic A (1998) Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev 17:91-106
26. Lala PK, Chakraborty C (2001) Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2:149-156
27. Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA (2006) Tumor iNOS predicts poor survival in stage III melanoma patients. Int J Cancer 119:861-6
28. Inagaki R, Taniguchi T, Sakai T, Hayashi N, Ishii Y, Muramatsu I (1999) Anticancer drugs inhibit induction of NO synthase in rat in vivo. Gen Pharmacol 32:185-188
29. Jung ID, Lee JS, Yun SY, Park CG, Han JW, Lee HW, Lee HY (2002) Doxorubicin inhibits the production of nitric oxide by colorectal cancer cells. Arch Pharm Res 25:691-696
30. Jadeski LC, Chakraborty C, Lala PK (2003) Nitric oxide-mediated promotion of mammary tumour cell migration requires sequential activation of nitric oxide synthase, guanylate cyclase and mitogen-activated protein kinase. Int J Cancer 106:496-504
31. Wenzel U, Kuntz S, De Sousa UJ, Daniel H (2003) Nitric oxide suppresses apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions. Int J Cancer 106:666-675
32. Wang X, Michael D, de Murcia G, Oren M (2002) p53 Activation by nitric oxide involves down-regulation of Mdm2. J Biol Chem 277:15697-15702
33. Yang J, Richmond A (2001) Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res 61:4901-4909